Patents by Inventor Kathrin Skibbe

Kathrin Skibbe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • T cells with increased immunosuppression resistance
    Patent number: 10689620
    Abstract: This invention relates to the treatment of cancer in an individual by administration of a population of modified T cells that express a recombinant cAMP phosphodiesterase (PDE) or a fragment thereof and an antigen receptor which binds specifically to cancer cells in the individual. Populations of modified T cells and methods of producing populations of modified T cells are provided, along with pharmaceutical compositions and methods of treatment.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: June 23, 2020
    Assignee: ADAPTIMMUNE LIMITED
    Inventors: Bruno Laugel, Kathrin Skibbe
  • T Cells With Increased Immunosuppression Resistance
    Publication number: 20180298338
    Abstract: This invention relates to the treatment of cancer in an individual by administration of a population of modified T cells that express a recombinant cAMP phosphodiesterase (PDE) or a fragment thereof and an antigen receptor which binds specifically to cancer cells in the individual. Populations of modified T cells and methods of producing populations of modified T cells are provided, along with pharmaceutical compositions and methods of treatment.
    Type: Application
    Filed: April 9, 2018
    Publication date: October 18, 2018
    Inventors: Bruno Laugel, Kathrin Skibbe
  • T cells with increased immunosuppression resistance
    Patent number: 9976121
    Abstract: This invention relates to the treatment of cancer in an individual by administration of a population of modified T cells that express a recombinant cAMP phosphodiesterase (PDE) or a fragment thereof and an antigen receptor which binds specifically to cancer cells in the individual. Populations of modified T cells and methods of producing populations of modified T cells are provided, along with pharmaceutical compositions and methods of treatment.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: May 22, 2018
    Assignee: Adaptimmune Limited
    Inventors: Bruno Laugel, Kathrin Skibbe
  • T Cells with Increased Immunosuppression Resistance
    Publication number: 20180010095
    Abstract: This invention relates to the treatment of cancer in an individual by administration of a population of modified T cells that express a recombinant cAMP phosphodiesterase (PDE) or a fragment thereof and an antigen receptor which binds specifically to cancer cells in the individual.
    Type: Application
    Filed: September 22, 2017
    Publication date: January 11, 2018
    Inventors: Bruno Laugel, Kathrin Skibbe